Skip to content

Daily ventilation and optimization of the radiotherapy plan for esophageal cancer (ART-OES 2).

Adding regularized breathing to Adaptive RadioTherapy in patients with esophageal OESophageal cancer: a single-center feasibility study (ART-OES 2). - ART-OES 2

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58533
Enrollment
35
Registered
2025-03-17
Start date
2026-08-04
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer Esophageal cancer

Interventions

After informed consent and before treatment, patients will be trained in one session to feel safe and comfortable while being non-invasively mechanically ventilated via a face mask with an antibacteri

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age =18 yearsCondition: WHO performance score 0-1 Biopsy-proven carcinoma of the oesophagus or GOJ, stage cT2-4aN0-3M0 or cT1-4aN1-3M0Scheduled for neoadjuvant chemoradiotherapyConsidered fit for surgery (i.e. operable) by an Upper GI surgeonAdequate communication and understanding skills of Dutch languageSigned informed consent (IC)

Exclusion criteria

Exclusion criteria: A history of severe COPD (GOLD IV)A history of pulmonary hypertensionKnown increased intracranial pressureHistory of pneumothorax in the past 5 yearsOesophageal stent in situPatients unable to cooperate or to lie flat on their back for up to 30 minutesPrevious irradiation overlapping with intended new radiotherapy fields

Design outcomes

Primary

MeasureTime frame
The primary objective of this phase II study is to investigate the feasibility of combining a standard of care oART approach with experimental NIMV-induced RB during radiotherapy for patients undergoing neoadjuvant CRT for oesophageal or GOJ cancer. Feasibility is defined as finding that =80% of patients complete at least 18 out of 23 fractions using oART with NIMV-induced RB.

Secondary

MeasureTime frame
Secondary objectives include the assessment of patient comfort, treatment toxicity and treatment time. Also, the dosimetric impact of oART with NIMV-induced RB compared to a simulated conventional non-oART non-NIMV approach and an oART non-NIMV approach in the same patients will be evaluated. Other secondary endpoints include quantification of interfraction and intrafraction motion patterns of the target volume, margins and surrounding organs. 

Countries

Netherlands

Contacts

Public ContactP.S.N. van Rossum

Amsterdam UMC

p.s.n.vanrossum@amsterdamumc.nl06-50087516

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 25, 2026